Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07623798 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Interventions modified · Start date changed from estimate of Jun 5, 2026 to Jun 11, 2026 · Eligibility criteria expanded, about 13 words · 3 more Show 6 more changesShow less
    • Interventions modified
    • Start date changed from estimate of Jun 5, 2026 to Jun 11, 2026
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 5 of 19 entries
    • Site details revised
    • Study description expanded, about 4 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate how well IBI3003 works when compared with the investigator's choice regimen (DPd or PVd or SVd)
Trial Details
NCT Number NCT07623798
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Relapsed or Refractory Multiple Myeloma
Enrollment 255 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov